Innoviva Stock Price, News & Analysis (NASDAQ:INVA)

$14.56 0.02 (0.14 %)
(As of 01/17/2018 04:21 AM ET)
Previous Close$14.54
Today's Range$14.42 - $14.76
52-Week Range$10.30 - $14.87
Volume1.07 million shs
Average Volume687,390 shs
Market Capitalization$1.57 billion
P/E Ratio18.43
Dividend YieldN/A
Beta2.52

About Innoviva (NASDAQ:INVA)

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:INVA
CUSIP88338T10
Phone+1-650-2389600

Debt

Debt-to-Equity Ratio-2.59%
Current Ratio6.71%
Quick Ratio6.71%

Price-To-Earnings

Trailing P/E Ratio18.4303797468354
Forward P/E Ratio13.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$133.57 million
Price / Sales11.77
Cash Flow$0.70 per share
Price / Cash20.71
Book Value($3.26) per share
Price / Book-4.47

Profitability

Trailing EPS$0.79
Net Income$59.53 million
Net Margins52.91%
Return on Equity-33.55%
Return on Assets26.40%

Miscellaneous

Employees14
Outstanding Shares108,010,000

Innoviva (NASDAQ:INVA) Frequently Asked Questions

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.34 by $0.13. The biotechnology company had revenue of $48.64 million for the quarter, compared to analysts' expectations of $57.18 million. Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The firm's quarterly revenue was up 46.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.13 EPS. View Innoviva's Earnings History.

When will Innoviva make its next earnings announcement?

Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Innoviva.

Where is Innoviva's stock going? Where will Innoviva's stock price be in 2018?

5 analysts have issued twelve-month price targets for Innoviva's shares. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's share price to reach $13.00 in the next twelve months. View Analyst Ratings for Innoviva.

Who are some of Innoviva's key competitors?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:

  • William H. Waltrip, Independent Chairman of the Board (Age 78)
  • Eric D'Esparbes, Chief Financial Officer, Senior Vice President (Age 49)
  • Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer (Age 59)
  • Michael E. Faerm, Senior Vice President and Chief Business Officer (Age 50)
  • Michael W. Aguiar, President, Chief Executive Officer, Director (Age 50)
  • George W. Bickerstaff III, Independent Director (Age 62)
  • Barbara G. Duncan, Independent Director
  • Catherine J. Friedman, Independent Director (Age 56)
  • Odysseas D. Kostas M.D., Independent Director (Age 43)
  • Patrick G. LePore, Independent Director (Age 62)

Who owns Innoviva stock?

Innoviva's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.17%) and Convergence Investment Partners LLC (0.12%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, James L Tyree, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

Who bought Innoviva stock? Who is buying Innoviva stock?

Innoviva's stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Convergence Investment Partners LLC. View Insider Buying and Selling for Innoviva.

How do I buy Innoviva stock?

Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of Innoviva stock can currently be purchased for approximately $14.56.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.57 billion and generates $133.57 million in revenue each year. The biotechnology company earns $59.53 million in net income (profit) each year or $0.79 on an earnings per share basis. Innoviva employs 14 workers across the globe.

How can I contact Innoviva?

Innoviva's mailing address is 2000 Sierra Point Pkwy Ste 500, BRISBANE, CA 94005-1830, United States. The biotechnology company can be reached via phone at +1-650-2389600 or via email at [email protected]


MarketBeat Community Rating for Innoviva (INVA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Innoviva (NASDAQ:INVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.002.50
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.00$13.00$13.50
Price Target Upside: 0.46% downside0.46% downside11.86% downside14.50% upside

Innoviva (NASDAQ:INVA) Consensus Price Target History

Price Target History for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017Deutsche BankInitiated CoverageHold$13.00N/AView Rating Details
10/24/2017Robert W. BairdReiterated RatingHold$13.00N/AView Rating Details
10/23/2017CowenSet Price TargetBuy$16.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingUnderweight$7.00 -> $8.00N/AView Rating Details
9/15/2017Stifel NicolausReiterated RatingHold -> NeutralLowView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Innoviva (NASDAQ:INVA) Earnings History and Estimates Chart

Earnings by Quarter for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ INVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018$0.38N/AView Earnings Details
10/25/2017Q3 2017$0.34$0.21$57.18 million$48.64 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.28$0.30$50.53 million$58.60 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.27$0.15$47.66 million$40.50 millionViewN/AView Earnings Details
2/9/2017Q4 2016$0.19$0.22$40.72 million$43.60 millionViewListenView Earnings Details
10/27/2016Q316$0.19$0.16$38.71 million$33.30 millionViewListenView Earnings Details
7/28/2016Q216$0.12$0.17$31.13 million$32.47 millionViewListenView Earnings Details
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details
5/6/2015Q115($0.08)($0.09)$8.64 million$6.90 millionViewListenView Earnings Details
2/18/2015Q414($0.14)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details
10/30/2014Q314($0.15)($0.19)$5.06 million$1.00 millionViewN/AView Earnings Details
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details
8/6/2014Q214($0.53)($0.18)$4.39 million$0.93 millionViewN/AView Earnings Details
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details
4/26/2012$1.02$0.93ViewN/AView Earnings Details
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.28)($0.28)ViewN/AView Earnings Details
2/15/2011Q4 2010($0.28)($0.25)ViewN/AView Earnings Details
10/21/2010Q3 2010($0.27)($0.29)ViewN/AView Earnings Details
7/22/2010Q2 2010($0.27)($0.28)ViewN/AView Earnings Details
4/21/2010Q1 2010($0.28)($0.35)ViewN/AView Earnings Details
2/11/2010Q4 2009($0.34)($0.35)ViewN/AView Earnings Details
10/27/2009Q3 2009($0.34)($0.35)ViewN/AView Earnings Details
7/23/2009Q2 2009($0.33)($0.35)ViewN/AView Earnings Details
4/22/2009Q1 2009($0.29)($0.29)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.36)($0.26)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.35)($0.34)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.48)($0.36)ViewN/AView Earnings Details
4/21/2008Q1 2008($0.47)($0.49)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.56)($0.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Innoviva (NASDAQ:INVA) Earnings Estimates

Current Year EPS Consensus Estimate: $1.08 EPS
Next Year EPS Consensus Estimate: $2.01 EPS

Dividends

Innoviva (NASDAQ:INVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2015quarterly$0.257.01%9/8/20159/10/20159/30/2015
5/7/2015quarterly$0.256.43%6/10/20156/12/20156/30/2015
2/24/2015quarterly$0.255.85%3/10/20153/12/20153/31/2015
10/31/2014quarterly$0.256.24%11/21/201411/25/201412/23/2014
8/6/2014quarterly$0.258/26/20148/28/20149/18/2014
(Data available from 1/1/2013 forward)

Insider Trades

Innoviva (NASDAQ INVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 74.41%
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ INVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2017Michael W AguiarInsiderSell12,022$13.13$157,848.86980,907View SEC Filing  
11/21/2017Eric DesparbesCFOSell15,285$13.28$202,984.80337,027View SEC Filing  
11/21/2017George B AbercrombieVPSell5,215$13.26$69,150.90263,866View SEC Filing  
8/21/2017Eric DesparbesCFOSell1,825$12.20$22,265.00344,993View SEC Filing  
5/22/2017Eric DesparbesCFOSell1,825$11.85$21,626.25352,588View SEC Filing  
5/22/2017Theodore J Jr. WitekVPSell7,815$12.01$93,858.15251,968View SEC Filing  
2/21/2017Eric DesparbesCFOSell1,825$12.07$22,027.75356,121View SEC Filing  
11/22/2016Theodore L Witek JrVPSell3,700$10.84$40,108.00157,131View SEC Filing  
11/21/2016Eric DesparbesCFOSell1,800$10.89$19,602.00View SEC Filing  
8/22/2016Eric DesparbesCFOSell3,700$11.77$43,549.00239,893View SEC Filing  
5/18/2016James L TyreeDirectorSell813$10.47$8,512.1150,697View SEC Filing  
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59690,106View SEC Filing  
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Innoviva (NASDAQ INVA) News Headlines

Source:
DateHeadline
Innoviva Inc (INVA) Expected to Announce Quarterly Sales of $66.75 MillionInnoviva Inc (INVA) Expected to Announce Quarterly Sales of $66.75 Million
www.americanbankingnews.com - January 14 at 9:58 AM
Innoviva Inc (INVA) Receives Consensus Rating of "Hold" from BrokeragesInnoviva Inc (INVA) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 14 at 1:32 AM
 Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share
www.americanbankingnews.com - January 12 at 9:30 AM
Head-To-Head Analysis: Tetraphase Pharmaceuticals (TTPH) vs. Innoviva (INVA)Head-To-Head Analysis: Tetraphase Pharmaceuticals (TTPH) vs. Innoviva (INVA)
www.americanbankingnews.com - January 10 at 8:02 AM
Validea Joel Greenblatt Strategy Daily Upgrade Report - 1/5/2018 ... - NasdaqValidea Joel Greenblatt Strategy Daily Upgrade Report - 1/5/2018 ... - Nasdaq
www.nasdaq.com - January 5 at 8:01 AM
Innoviva Sees RS Rating Rise To 74Innoviva Sees RS Rating Rise To 74
finance.yahoo.com - December 27 at 11:40 AM
Zacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per ShareZacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Earnings of $0.45 Per Share
www.americanbankingnews.com - December 26 at 7:21 PM
Innoviva Earns Relative Strength Rating UpgradeInnoviva Earns Relative Strength Rating Upgrade
finance.yahoo.com - December 22 at 11:26 AM
Innoviva (INVA) Upgraded at BidaskClubInnoviva (INVA) Upgraded at BidaskClub
www.americanbankingnews.com - December 21 at 11:28 PM
ETFs with exposure to Innoviva, Inc. : December 21, 2017ETFs with exposure to Innoviva, Inc. : December 21, 2017
finance.yahoo.com - December 21 at 3:24 PM
Innoviva Inc (INVA) Given Average Recommendation of "Hold" by AnalystsInnoviva Inc (INVA) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 20 at 1:28 AM
Amicus Therapeutics (FOLD) and Innoviva (INVA) Financial ContrastAmicus Therapeutics (FOLD) and Innoviva (INVA) Financial Contrast
www.americanbankingnews.com - December 14 at 1:28 PM
Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : December 12, 2017Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : December 12, 2017
finance.yahoo.com - December 12 at 7:49 AM
$66.75 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter$66.75 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter
www.americanbankingnews.com - December 11 at 1:00 PM
Analyzing Innoviva (INVA) and Johnson & Johnson (JNJ)Analyzing Innoviva (INVA) and Johnson & Johnson (JNJ)
www.americanbankingnews.com - December 9 at 9:36 AM
Innoviva, Inc. (INVA) Expected to Post Earnings of $0.45 Per ShareInnoviva, Inc. (INVA) Expected to Post Earnings of $0.45 Per Share
www.americanbankingnews.com - December 9 at 5:30 AM
Insider Selling: Innoviva, Inc. (INVA) Insider Sells 12,022 Shares of StockInsider Selling: Innoviva, Inc. (INVA) Insider Sells 12,022 Shares of Stock
www.americanbankingnews.com - December 5 at 7:14 PM
ETFs with exposure to Innoviva, Inc. : December 1, 2017ETFs with exposure to Innoviva, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 3:25 PM
Innoviva, Inc. :INVA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Innoviva, Inc. :INVA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 11:58 AM
Comparing Innoviva (INVA) and Its RivalsComparing Innoviva (INVA) and Its Rivals
www.americanbankingnews.com - November 27 at 5:22 PM
Analyzing Innoviva (INVA) & Its CompetitorsAnalyzing Innoviva (INVA) & Its Competitors
www.americanbankingnews.com - November 25 at 11:04 PM
Innoviva, Inc. (INVA) Receives Average Recommendation of "Hold" from BrokeragesInnoviva, Inc. (INVA) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 25 at 1:48 AM
Innoviva, Inc. (INVA) Expected to Post Quarterly Sales of $63.27 MillionInnoviva, Inc. (INVA) Expected to Post Quarterly Sales of $63.27 Million
www.americanbankingnews.com - November 23 at 12:52 PM
Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : November 22, 2017Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : November 22, 2017
finance.yahoo.com - November 23 at 2:26 AM
George B. Abercrombie Sells 5,215 Shares of Innoviva, Inc. (INVA) StockGeorge B. Abercrombie Sells 5,215 Shares of Innoviva, Inc. (INVA) Stock
www.americanbankingnews.com - November 22 at 8:44 PM
Innoviva, Inc. (INVA) CFO Sells $202,984.80 in StockInnoviva, Inc. (INVA) CFO Sells $202,984.80 in Stock
www.americanbankingnews.com - November 22 at 8:23 PM
Innoviva, Inc. (INVA) Earns Hold Rating from Analysts at Deutsche Bank AGInnoviva, Inc. (INVA) Earns Hold Rating from Analysts at Deutsche Bank AG
www.americanbankingnews.com - November 20 at 8:52 PM
Innoviva Reaches Analyst Target PriceInnoviva Reaches Analyst Target Price
www.thestreet.com - November 20 at 4:43 PM
Corporate News Blog - GlaxoSmithKline and Innoviva’s Trelegy Ellipta Gets Marketing Authorization for the Treatment of COPD in EuropeCorporate News Blog - GlaxoSmithKline and Innoviva’s Trelegy Ellipta Gets Marketing Authorization for the Treatment of COPD in Europe
finance.yahoo.com - November 20 at 4:43 PM
Comparing Innoviva (INVA) & Its RivalsComparing Innoviva (INVA) & Its Rivals
www.americanbankingnews.com - November 19 at 9:28 AM
Glaxos Triple Therapy COPD Inhaler Gets Marketing Nod in EUGlaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
www.zacks.com - November 18 at 2:23 AM
Innoviva (INVA) and Its Peers Head to Head SurveyInnoviva (INVA) and Its Peers Head to Head Survey
www.americanbankingnews.com - November 16 at 7:10 PM
Largest Shareholders of GlaxcoSmithKlineLargest Shareholders of GlaxcoSmithKline
finance.yahoo.com - November 9 at 6:53 AM
Adamis Pharmaceuticals Corporation (ADMP) & Innoviva (INVA) Head-To-Head ComparisonAdamis Pharmaceuticals Corporation (ADMP) & Innoviva (INVA) Head-To-Head Comparison
www.americanbankingnews.com - November 7 at 7:44 PM
Innoviva to Participate at the Credit Suisse and Stifel Annual Healthcare Conferences in NovemberInnoviva to Participate at the Credit Suisse and Stifel Annual Healthcare Conferences in November
finance.yahoo.com - November 2 at 2:29 AM
Innoviva, Inc. (INVA) Receives Average Recommendation of "Hold" from AnalystsInnoviva, Inc. (INVA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 31 at 1:34 AM
Innoviva, Inc. – Value Analysis (NASDAQ:INVA) : October 27, 2017Innoviva, Inc. – Value Analysis (NASDAQ:INVA) : October 27, 2017
finance.yahoo.com - October 28 at 7:07 AM
Innoviva, Inc. (INVA) Posts Quarterly  Earnings Results, Misses Estimates By $0.13 EPSInnoviva, Inc. (INVA) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - October 26 at 3:46 PM
Form 8-K Innoviva, Inc. For: Oct 25Form 8-K Innoviva, Inc. For: Oct 25
www.streetinsider.com - October 26 at 2:06 PM
Oversold Conditions For Innoviva (INVA)Oversold Conditions For Innoviva (INVA)
www.nasdaq.com - October 26 at 2:06 PM
Innovivas (INVA) CEO Michael Aguiar on Q3 2017 Results - Earnings Call TranscriptInnoviva's (INVA) CEO Michael Aguiar on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 26 at 2:06 PM
Innoviva, Inc. to Host Earnings CallInnoviva, Inc. to Host Earnings Call
finance.yahoo.com - October 26 at 2:06 PM
Innoviva Reports Third Quarter 2017 Financial Results and Provides Business UpdatesInnoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates
finance.yahoo.com - October 26 at 2:06 PM
Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?
finance.yahoo.com - October 26 at 2:06 PM
Innoviva misses 3Q profit forecastsInnoviva misses 3Q profit forecasts
finance.yahoo.com - October 26 at 2:06 PM
Edited Transcript of INVA earnings conference call or presentation 25-Oct-17 9:00pm GMTEdited Transcript of INVA earnings conference call or presentation 25-Oct-17 9:00pm GMT
finance.yahoo.com - October 26 at 2:06 PM
Innoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : October 26, 2017Innoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : October 26, 2017
finance.yahoo.com - October 26 at 2:06 PM
Innoviva, Inc. (INVA) Rating Increased to Buy at Zacks Investment ResearchInnoviva, Inc. (INVA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - October 26 at 12:31 AM
Robert W. Baird Reaffirms "Hold" Rating for Innoviva, Inc. (INVA)Robert W. Baird Reaffirms "Hold" Rating for Innoviva, Inc. (INVA)
www.americanbankingnews.com - October 24 at 4:50 PM
Cowen and Company Reiterates "$16.00" Price Target for Innoviva, Inc. (INVA)Cowen and Company Reiterates "$16.00" Price Target for Innoviva, Inc. (INVA)
www.americanbankingnews.com - October 24 at 3:32 PM

SEC Filings

Innoviva (NASDAQ:INVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Innoviva (NASDAQ:INVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Innoviva (NASDAQ INVA) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.